Original Research Article

Daily versus intermittent Anti-tuberculous Treatment in Pediatric Tuberculosis: A Comparative Study

Author
Dr Ambika Sood
Department Of Pediatrics, Indira Gandhi Medical College Shimla
*Corresponding Author
Dr Ambika Sood
Address: 98, Lower Bazaar, Shimla. Pin-171001, India

Abstract

Background: The World Health Organization (WHO) declared tuberculosis (TB) a global public health emergency in 1993. It is the second leading cause of death from an infectious disease worldwide and leading cause of ill-health among millions of people. Treatment options of tuberculosis include intermittent therapy in DOTS and daily therapy. Aim of our study is to compare daily versus intermittent antituberculous treatment.

Methods: This observational prospective study was conducted at Indira Gandhi Medical College, Shimla. Detailed information was collected on predesigned proformas and results were compiled and evaluated on master chart.

Results: 460 children were diagnosed with various forms of tuberculosis, out of which 82 children fulfilling the inclusion criteria were enrolled in this study. These were divided into two groups (Group 1 and Group 2). The mean age at the time of enrollment was 10.34 years. 42 (53.16%) were males and 37 (46.83%) females, with a sex ratio of M:F=1.1:1. Sputum negativity in the daily therapy group showed statistical significance with a p value of < .05, an odds ratio of 0.17 with Confidence Intervals: 0.02 – 0.94.

Conclusion: Tuberculosis remains a major cause of mortality and morbidity in Pediatric population. Daily therapy may be a futuristic treatment option with better results.

Keywords: Tuberculosis Pediatric, Daily, Intermittent, Gastric aspirate.

Introduction
The World Health Organization (WHO) declared tuberculosis (TB) a global public health emergency in 1993. It is the second leading cause of death from an infectious disease worldwide and leading cause of ill-health among millions of people. Latest WHO estimates reveal that in 2013, an estimated 9.0 million people developed TB and of these 1.5 million died from the disease, 360000 of them being HIV positive. Childhood Tuberculosis remains an important cause of morbidity and mortality in the developing countries. In 2013, there were an estimated 550,000 cases (about 6% of the total number) 9.0 million incident cases and 80,000 deaths among children. Data on TB in Indian children are scarce. Tuberculin surveys are the only surveys which suggest that the annual risk of TB infection
is above 1.5%.\cite{5,6} The aim of anti-tubercul treatment (ATT) in adults and children is alike to cure the patient of TB, minimize the spread to others and avoid the development of drug resistance. Most of the clinical trials of ATT have only been carried out in adults with microbiologically proven pulmonary TB, following objective microbiological case definitions and treatment outcomes. Treatment protocols of tuberculosis include DOTS intermittent therapy and daily regimen.

A meta-analysis comparing daily and intermittent (mostly twice-weekly) regimens conducted at All India Institute of Medical Sciences (AIIMS), New Delhi over a period of five years 2000-2005 in children age 2-15yrs. It concluded that twice weekly intermittent short course therapy is less likely to cure tuberculosis in children as compared to daily therapy (14). Therefore, keeping in view the limited data from our country, we aim to compare the effectiveness of intermittent therapy with daily short course chemotherapy in childhood tuberculosis, in the age group between 1-18 yrs, in achieving cure/significant improvement in children, and side effect profile in either therapy.

Aims & Objectives

1. To Compare the Effectiveness of Intermittent (thrice weekly) versus Daily short course chemotherapy in childhood tuberculosis in the population age group 1-18yrs in achieving cure/significant improvement in children.
2. To compare incidence of side effects profile in both the groups.

Methodology

This prospective observational study was conducted in the Department of Pediatrics, and Dept. of Pulmonary Medicine, Indira Gandhi Medical College Shimla, Himachal Pradesh, India over a period of one year w. e. f. June 2013- May 2014. Patients aged 1-18yrs, with confirmed tuberculosis attending to the outpatient as well as in-patient department were enrolled in the study. After confirmation of the diagnosis of pulmonary/extra-pulmonary TB, patients were administered ATT, using the inclusion criteria.

Inclusion Criteria

All children between 1-18yrs diagnosed as Pulmonary/Extrapulmonary tuberculosis were administered Intermittent / Daily Chemotherapy, after allocation of the children into 2 groups. Informed consent was taken in all the cases from the parents/caregivers. These patients were randomly allocated into two treatment groups, one group received DOTS therapy (group 1), and the second group received Daily therapy (group 2) for a period of 6 months. Based on the age of the patients enrolled, they were further subdivided into 3 groups, 1-5 yrs, 6-10 yrs and 11-18 yrs. The drugs used for treatment were Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E).

Following two dosing regimens were used in the DOTS therapy group based on the weight of the child as per Revised National Tuberculosis Control Programme (RNTCP) pediatric guidelines

1. PC 13(R-75mg, H-75mg, E-200 mg, Z-250 mg)
2. PC 14(R-150 mg, H-150 mg, E-400 mg, Z-500 mg)

In Daily therapy group drug doses used were Rifampicin – 10mg/kg. (maximum dose 600mg), Isoniazid– 10mg/kg.(maximum dose-300mg), Ethambutol–15-20mg/kg (maximum dose-2500mg), Pyrazinamide–15-30mg/kg (maximum dose-2000mg). The children were followed over the next 6 months for the comparison of efficacy of either treatment or side effect profile in both the therapies.

Follow up

These cases were assessed on the following points:

1. Subjective Improvement- improvement of initial symptoms e.g. afebrile, weight gain, increase in appetite.
3. Radiological improvement to be assessed by chest x-ray examination in all patients who had radiological signs earlier, smear-negative pulmonary TB cases at 2nd month and as needed.

4. Death – while on treatment or within 6 months after treatment

5. Adherence – seen by empty blister pack, color of urine or discontinuation of therapy for at least 1 month on their own accord.

6. Toxicity – adverse drug reactions requiring interruption / alteration of therapy

7. Relapse

**Data Analysis:** Data was collected on predesigned proforma and transferred to excel sheet for further processing and analysis. SSPS version 22(American) and epi info version 7 software were used for analysis.

**Results**

Four hundred and sixty children were diagnosed with various forms of tuberculosis, out of which 82 children fulfilling the inclusion criteria were enrolled in this study. Three subjects (two in Group 1 and one in Group 2) were lost to follow up and the rest 79 patients completed the study protocol.

**Baseline characteristics of enrolled children**

Both the study groups were sub-divided into three age groups (Table 1). The mean age at the time of enrollment was 10.34 years with a standard deviation of 4.69 (± 2S.D) in Group 1 and 10.18 years with standard deviation of 4.66 (±2S.D) in Group 2, which is comparable.

<table>
<thead>
<tr>
<th>Age group</th>
<th>GROUP 1 (n= 39)</th>
<th>GROUP 2 (n = 40)</th>
<th>TOTAL (n=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5 yrs</td>
<td>9 (11.39%)</td>
<td>9(11.39%)</td>
<td>18</td>
</tr>
<tr>
<td>6-10 yrs</td>
<td>9 (11.39%)</td>
<td>10(12.65%)</td>
<td>19</td>
</tr>
<tr>
<td>11-18 yrs</td>
<td>21 (26.58%)</td>
<td>21(26.58%)</td>
<td>42</td>
</tr>
</tbody>
</table>

**Figure 1:** Sex Wise Distribution of cases

42 (53.16%) were males and 37 (46.83%) females, with a sex ratio of M:F=1.1:1(Figure 1). Of the total 42 males, 22 (52.38%) were in Group 1 whereas remaining 20 (47.62%) were in Group 2. Female children in Group 1 were 17 (45.95%) and 20 (54.05%) in Group 2. (Figure 2)

**Figure 2:** Sex wise distribution of cases in Group 1 and Group 2.
Profile of children with Tuberculosis

Children were diagnosed as Pulmonary (PTB), extra-pulmonary and disseminated tuberculosis. Fifty-eight (73.41%) children had PTB, 19 (24.05%) children had extra-pulmonary tuberculosis and 2 (2.53%) children had disseminated tuberculosis at the time of enrollment (Table 2).

Table 2: Profile of children with Tuberculosis

<table>
<thead>
<tr>
<th>Age group</th>
<th>GROUP 1 (n=39)</th>
<th>GROUP 2 (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pulmonary (n=28)</td>
<td>Extra-pulmonary (n=10)</td>
</tr>
<tr>
<td>1-5 yrs</td>
<td>7 (12.07%)</td>
<td>2 (10.52%)</td>
</tr>
<tr>
<td>6-10 yrs</td>
<td>7 (12.07%)</td>
<td>2 (10.52%)</td>
</tr>
<tr>
<td>11-18 yrs</td>
<td>14 (24.14%)</td>
<td>6 (31.57%)</td>
</tr>
</tbody>
</table>

The diagnosis of pulmonary tuberculosis was based on the sputum/gastric lavage positivity, characteristic of pleural aspirate as well as other radiological signs. 35 (60.34%) children of 58 were sputum/ lavage positive, out of which 18 (51.42%) were in the Group 1 and 17 (48.57%) were in the Group 2. Majority of sputum positive cases (48.57%) were adolescents. Of the 58 children with pulmonary TB, 48 children had radiological signs. Pleural effusion was the commonest radiological abnormality seen in 21 (43.75%) children, followed by adenitis in 8 (16.66%) and parenchymal lesions in 19 (39.58%) as shown in Table 4. Out of 19 children with extra-pulmonary TB, 9 (47.36%) had ascitis, 3 (15.79%) had arthritis, 2 (10.52%) had lymph node TB and 5 (26.32%) had mixed presentation.

Follow up

Follow up sputum smears were done in all sputum/lavage positive cases as per RNTCP guidelines. In Group 1, 55.55% (n=10) became sputum negative at the end of intensive phase of therapy, 83.33% (n=15) by 3 months, 94.44% (n=17) at the end of 4 months and 100% by 5 months of therapy. While in Group 2, 88.23% showed sputum smear conversion by 2 months, and 100% by 3 months of therapy (Table 3).

In this study, sputum negativity in the daily therapy group showed statistical significance with a p value of < .05, an odds ratio of 0.17 with Confidence Intervals : 0.02 – 0.94.

Table 3: Cumulative frequency of sputum negativity

<table>
<thead>
<tr>
<th>Time after start of ATT</th>
<th>Group 1 (n=18)</th>
<th>Group 2 (n=17)</th>
<th>P value</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 months</td>
<td>10 (55.55%)</td>
<td>15 (88.23%)</td>
<td>0.04</td>
<td>0.17 (0.02-0.94)</td>
</tr>
<tr>
<td>3 months</td>
<td>5 (27.78%)</td>
<td>2 (11.76%)</td>
<td>0.27</td>
<td>2.8 (46-23.87)</td>
</tr>
<tr>
<td>4 months</td>
<td>2 (11.11%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5 months</td>
<td>1 (5.55%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Of the 79 study subjects, 48 (60.76%) had radiological signs, 45.83% were in Group 1 and 54.16% were in Group 2. In Group 1, 40.90% of children achieved radiological clearance at 2 months, 72.72% at the end of 3 months, 86.36% at 4 months and 90.90% at 5 months and 100% at the end of 6 months of therapy. In group 2, 57.69% had evidence of radiological clearance after completion of intensive phase, 65.38% at 3 months, 92.31% at 4 months, 96.16% at 5 months and one child had evidence of incomplete resolution at completion of therapy. The following
parameters as per protocol were assessed for the evaluation of subjective improvement: weight gain and resolution of symptoms. In the intensive phase, 82.05% (n=32) of the children showed symptomatic improvement in Group 1 compared to 90% (n=36) in Group 2, and 100% in both groups during the continuation phase.

**Adverse events**

Adverse reactions were documented in 30.37% (n=24) children, mainly in the intensive phase of therapy. Gastrointestinal intolerance was the commonest presentation seen in 25% (n=6) in Group 1 and 37.5% (n=9) in Group 2. The other recorded side effects were arthralgia in 29.16% (n=7), headache in 12.5% (n=3) and jaundice with raised transaminase levels [5 times the normal age specific values] in 8.33% (n=2) cases. In Group 1 raised transaminase levels were observed only during the intensive phase of therapy while in Group 2 they were also documented in the continuation phase. Adverse reactions were comparable in both the groups and statistically insignificant with a p value of >.05. During the study period and follow up, no relapse or death was reported in either of the groups.

**Outcome**

In this study, of the total 79 children, cure rates were comparable in both the groups. Time interval from the initiation of therapy to sputum negativity in Group 2 (on Daily therapy) was statistically significant compared to group 1 (p value 0.04). Subjective improvement, radiological clearance, adherence to therapy and profile of adverse events were comparable in both groups. There was no relapse or death in either of the groups during the study period as well as follow up.

**Discussion**

Initially, childhood TB was treated with daily therapy. However, with its success in adults, intermittent therapy (twice/thrice weekly) therapy has also been recommended in children. Till date many studies comparing daily and intermittent twice weekly therapy have been carried out in children, but hardly any study has compared WHO recommended thrice weekly (DOTS) with daily therapy. Therefore, we aim to compare the efficacy and outcome of the DOTS (thrice weekly) versus daily therapy in children from one to 18 years of age with regards to subjective improvement, rate of sputum conversion, radiological clearance as well as their side effect profile.

Seventy nine of the 82 cases enrolled between one to 18 years, completed the study. Mean age of the subjects was 10.2 years ± SD 4.6. Our study included 53.16% males. The male to female ratio was 1.1:1, which is similar to another study by Kansoy *et al.*, who reported a mean age of 7.6 yrs. [8] Sarin *et al.* in their study enrolled children with a mean age 11.2 years, but there was a female predominance. [9] Naude *et al.* in a study from South Africa reported a mean age of 2.1 years. [10] Ramachandran *et al.* included children <16 years (19), while Gocmen *et al.* included children between 6 months to 17 years age[11] and in a prospective study in USA, 2002, Al-Dossary *et al.* included children aged between 5 months to 17 years. [12] The slight gender bias in our study could be attributed to the fact that males are relatively better cared for in our society.

Thirty five children were sputum/lavage positive in the present study, 16 (45.71%) in the age group of 11-18 years and 9 (25.71%) in the 6-10 years age group. It was similar to a study by Sarin *et al.* who reported highest sputum positivity of 59% in the 11-14 years age group at the time of enrollment. [9] In the present study 28.57% were sputum/lavage positive in the 1-5 year age group supporting the fact that gastric aspirate and induced sputum specimens are useful tools for confirmation of the diagnosis of TB.

In Group 2, sputum negativity at the end of intensive phase was documented in 88.23% (15/17) patients in group 2 as compared to 55.55% (10/18) in group 1, which was statistically significant (p<0.04). In group 1, 100% patients showed sputum negativity at the end of 5 months of treatment, whereas 100% became negative by the end of 3 months of therapy in group 2.
therefore showing early sputum conversion in children on daily therapy compared to DOTS therapy. Limited number of studies in children has compared the rates of sputum conversion at the end of intensive phase. In studies conducted in adults, Salih et al. reported early conversion at the end of first month on daily therapy compared to intermittent therapy, however the difference being statistically insignificant. Prasad et al. also reported comparable sputum conversion rate at end of 2 months with both forms of therapy in adults. Qayyum et al. in a retrospective study carried out in Karachi reported sputum negativity at the end of intensive phase in 83% of subjects on intermittent therapy and 80% with daily therapy. It was statistically insignificant, but they used 2RHZE/2HE as intermittent therapy instead of 2HRZE/4HR3. Mandal et al. also showed comparable sputum conversion rate at end of intensive phase with both the regimens. Kashyap et al., in their study on DOTS regimen reported a sputum conversion rate of 87.27% at end of intensive phase. In the present study, the 100% cure rates were documented in both the groups, although 10.25% in group 1 required extension of intensive phase, whereas it was 7.5% in group 2, which is similar to other studies in children. Kansoy et al. reported cure rates of 100% in both the groups. Kumar et al. similarly reported high cure rates of 97% with intermittent regimen and 100% with daily regimen. Naudé et al. in a study reported cure rates of 89% and 97% in intermittent and daily regimen respectively. Ramachandran et al. reported a low cure rate of 60% with daily regimen and 48% in the intermittent therapy and it was insignificant. This may be attributed to the use of twice and thrice weekly regimen instead of one set regimen as laid down by WHO.

Of the 79 study subjects, 48 (60.76%) had radiological signs, 45.83% (n=22) were in Group 1 and 54.16% (n=26) were in Group 2. In Group 1 40.90% children achieved radiological clearance at 2 months, whereas in group 2, 57.69% had evidence of radiological clearance after completion of intensive phase and one child had incomplete resolution at completion of therapy, all the radiological assessment was done by a single radiologist. Indumati et al. in a study on children reported 13% residual radiological lesions. Diga Ret al in their study in children reported regression of radiological lesions in both groups with no significant difference. The reported adverse reactions in the study subjects was 30.37%, with 28.20% in group 1 and 40% in group 2, and majority of them were documented during the intensive phase of therapy. The commonest adverse effect was GI intolerance (nausea and vomiting), observed in 25% in group 1 and 37.5% in group 2, which is comparable to that in adults. 17.39% as reported in a study done by Mehrota, 28.7% in a study conducted at Singapore and 29.27% in the study done at Hongkong. Mandal et al reported the incidence of vomiting in 9.9% cases in intermittent therapy and none in subjects on daily therapy whereas Mohamed Taher et al also documented vomiting in 11% and gastritis in 9% of cases on DOTS therapy. Joint pains/ arthralgia was documented in 8.86% of the subjects in the present study, which is higher than that reported by Kumar et al in children, vomiting in 7.89% and joint pains in 2.63%. In our study all the subjects with arthralgia/ joint pains had normal serum uric acid levels. Jaundice and five times rise in serum transaminases was recorded in 2.53% of the cases in this study, one child in group 1 developed jaundice during intensive phase while one child in daily therapy developed jaundice during the continuation phase, both required discontinuation of only rifampicin and isoniazid, and their hepatic profile became normal after one month. These results are similar to those reported by Kansoy, et al where one child (1/33) had raised transaminases. Ramachandran, et al also reported 2 children of the 137 study subjects who developed jaundice one each in both the arms of the study. Mandal P, et al reported jaundice in 4.2% of the cases on intermittent therapy in adults.
Conclusion
Treatment of tuberculosis in children has undergone vast changes in the past few decades, with WHO recommending short course DOTS (three-weekly) therapy as an alternative to daily therapy. This study was unique in the sense that very few studies had compared daily and intermittent (three-weekly) therapy in children. The strength of this study was the documentation of early sputum conversion in children on daily therapy and, with regular and meticulous follow-up, the compliance can be as high as 100% and also highlights that anti-tubercular drugs are well tolerated by children.

Funding: No funding source
Conflicts of Interest: None declared
Ethical approval: This study was approved by institutional ethical committee.

Bibliography
15. Qayyum S, Ahmed, Ansari G. Comparing daily versus partially intermittent regimen of ATT in non HIV patients with new pulmonary tuberculosis in Dots
programme: OJHA Institute of Chest Diseases, Karachi.


